Prostate cancer, once metastasised, is difficult to treat. Surgical castration or hormonal manipulation provides initial success. However, patients progressively become hormone-resistant. During the last years, specific target proteins have been identified, which are involved in neoplastic development and tumour progression. In vitro investigation points to a close relationship between hormone resistance and activation of the mammalian target of rapamycin (mTOR) pathway . Analysis of tumour specimens has documented the association between mTOR variations and prostate cancer risk (Campa et al, 2011) . Indeed, most patients with prostate cancer have at least one activated component of the mTOR signalling pathway (Kremer et al, 2006; Dai et al, 2009) .
Hence, inactivating mTOR could become an attractive option to treat advanced prostate cancer. Among the number of mTOR inhibitors that have have been developed, the rapamycin analogues temsirolimus and RAD001 (everolimus) are the most prevalent in clinical use. Both have received US Food and Drug Administration approval, which however, is restricted to the treatment of advanced renal cell carcinoma. The relevance of temsirolimus and RAD001 in treating prostate cancer is still unclear. Although preclinical studies show mTOR inhibitors reverting prostatic neoplasia and reducing cell growth and proliferation (Morgan et al, 2009) , the clinical experience of mTOR inhibition in men with castrate-resistant prostate cancer has been disappointing. Only a few patients have benefited from an mTOR inhibition-based regimen, and disease progression inevitably occured during treatment (Amato et al, 2008; Armstrong et al, 2010) . It has, therefore, been argued that chronic drug exposure triggers the development of resistance, ultimately limiting the utility of mTOR inhibitors (Amato et al, 2008) . Knowledge about the precise mechanism of resistance, however, is limited. Based on a RAD001-resistant prostate cancer cell line, we recently reported that drug non-responsiveness is characterised by an increased level of cdk1 and cyclin B, which counteracts growth-blocking effects of this drug (Tsaur et al, 2011) . These studies have now been extended to explore the consequences of RAD001 resistance on the metastatic behaviour of prostate tumour cells. Additionally, the activity of RAD001-target proteins, as well as the expression pattern of a and b integrin adhesion receptors in resistant and non-resistant tumour cells, was analysed.
MATERIALS AND METHODS

Cell culture
The human prostate tumour cell line PC3 was obtained from DSMZ (Braunschweig, Germany) . Tumour cells were grown and subcultured in RPMI 1640 (Gibco/Invitrogen, Karlsruhe, Germany) containing 10% fetal calf serum (FCS), 2% HEPES buffer (1 M, pH 7.4), 2% glutamine and 1% penicillin/streptomycin. The RAD001-resistant subline was developed by 12 months of exposure to RAD001, starting at 1 nM and increasing stepwise to 1 mM. The control cells were designated PC3 par , the resistant variant was termed PC3
res . Human endothelial cells (HUVECs) were isolated from human umbilical veins and harvested by enzymatic treatment with dispase (Gibco/Invitrogen). Human endothelial cells were grown in Medium 199 (M199; Biozol, Munich, Germany), supplemented with 10% FCS, 10% pooled human serum, 20 mg ml À 1 endothelial cell growth factor (Boehringer, Mannheim, Germany), 0.1% heparin, 100 ng ml À 1 gentamycin and 20 mM HEPES buffer (pH 7.4). Subcultures from passages 2-6 were selected for experimental use.
RAD001
RAD001 (provided by Novartis Pharma AG, Basel, Switzerland) was dissolved in DMSO as 10 mM stock solution and stored in aliquots at À 20 1C. Prior to the experiments, RAD001 was diluted in cell culture medium. To analyse the influence of RAD001 on chemotactic movement, migration and invasion of PC3 par versus PC3 res cells, cell culture medium of PC3 res cells containing 1 mM RAD001 was replaced by RAD001-free medium to avoid unspecific effects. A medium change was also carried out in the PC3 par cell culture system. After 3 days, 5 nM RAD001 was added to both PC3 par versus PC3 res cells (controls were treated with fresh medium without RAD001) and chemotactic movement, migration and invasion were analysed.
To exclude toxic effects of the compound, cell viability was determined by trypan blue (Gibco/Invitrogen). For apoptosis detection, the expression of annexin V/propidium iodide (PI) was evaluated using the Annexin V-FITC Apoptosis Detection kit (BD Pharmingen, Heidelberg, Germany). Tumour cells were washed twice with PBS and then incubated with 5 ml of Annexin V-FITC and 5 ml of PI in the dark for 15 min at room temperature. Cells were analysed on a FACScalibur (BD Biosciences, Heidelberg, Germany). The percentage of apoptotic cells (early and late) in each quadrant was calculated using CellQuest software (BD Biosciences).
Tumour cell adhesion
To analyse tumour cell adhesion, HUVECs were transferred to sixwell multiplates (Falcon Primaria; BD Biosciences) in complete HUVEC medium. When confluency was reached, PC3 par or PC3 res cells were detached from the culture flasks by accutase treatment (PAA Laboratories, Cölbe, Germany) and 0.5 Â 10 6 cells were then added to the HUVEC monolayer for 30, 60 or 120 min. Subsequently, non-adherent tumour cells were washed off using warmed (37 1C) Medium 199. The remaining cells were fixed with 1% glutaraldehyde. Adherent tumour cells were counted in five different fields of a defined size (5 Â 0.25 mm 2 ) using a phase contrast microscope and the mean cellular adhesion rate was calculated.
Attachment to extracellular matrix components
Six-well plates were coated with collagen G (extracted from calfskin, consisting of 90% collagen type I and 10% collagen type III; seromed; diluted to 400 mg ml À 1 in PBS), laminin (derived from the Engelbreth-Holm-Swarm mouse tumour; diluted to 50 mg ml À 1 in PBS; BD Biosciences) or fibronectin (derived from human plasma; diluted to 50 mg ml À 1 in PBS; BD Biosciences) overnight. Unspecific cell binding was evaluated by culture plates treated with poly-Dlysine (Nunc, Wiesbaden, Germany). Plastic dishes were served as the background control. Plates were washed with 1% bovine serum albumin (BSA) in PBS to block nonspecific cell adhesion. Thereafter, 0.5 Â 10 6 tumour cells were added to each well for 60 min. Subsequently, non-adherent tumour cells were washed off, the remaining adherent cells were fixed with 1% glutaraldehyde and counted microscopically. The mean cellular adhesion rate, defined by adherent cells coated well À adherent cells background , was calculated from five different observation fields.
Measurement of tumour cell motility (chemotaxis), migration and invasion
Serum-induced chemotactic movement was examined using six-well Transwell chambers (Greiner, Frickenhausen, Germany) with 8-mm pores. A total of 0.5 Â 10 6 PC3 par versus PC3 res cells per ml were placed in the upper chamber in serum-free medium. To evaluate cell migration, Transwell chambers were precoated with collagen (400 mg ml À 1 ). Cell invasion was explored by coating the Transwell chambers with collagen (400 mg ml À 1 ), which were then overlaid with HUVEC. The lower chamber contained 10% serum. After 20 h incubation, the upper surface of the Transwell membrane was gently wiped with a cotton swab to remove nonmigrating cells. Cells, which had moved to the lower surface of the membrane, were stained using hematoxylin and counted microscopically. The mean chemotaxis, migration or invasion rate was calculated from five different observation fields.
Integrin surface expression
PC3
par versus PC3 res cells were washed in blocking solution (PBS, 0.5% BSA) and then incubated for 60 min at 4 1C with phycoerythrin (PE)-conjugated monoclonal antibodies directed against the following integrin subtypes: anti-a1 (IgG1; clone SR84, dilution 1 : 1000), anti-a2 (IgG2a; clone 12F1-H6, dilution 1 : 250), anti-a3 (IgG1; clone C3II.1, dilution 1 : 1000), anti-a4 (IgG1; clone 9F10, dilution 1 : 200), anti-a5 (IgG1; clone IIA1, dilution 1 : 5000), anti-a6 (IgG2a; clone GoH3, dilution 1 : 200), anti-b1 (IgG1; clone MAR4, dilution 1 : 2500), anti-b3 (IgG1; clone VI-PL2, dilution 1 : 2500) or anti-b4 (IgG2a; clone 439-9B, dilution 1 : 250; all: BD Biosciences). Integrin expression of tumour cells was then measured using a FACscan (BD Biosciences; FL-2H (log) channel histogram analysis; 1 Â 10 4 cells per scan) and expressed as mean fluorescence units. A mouse IgG1-PE (MOPC-21) or IgG2a-PE (G155-178; all: BD Biosciences) was used as an isotype control.
Western blot analysis
To explore the integrin protein level after 24 h drug incubation, tumour cell lysates were applied to a 7% polyacrylamide gel and electrophoresed for 90 min at 100 V. The protein was then transferred to nitrocellulose membranes. After blocking with non-fat dry milk for 1 h, the membranes were incubated overnight with the monoclonal antibodies listed above. Additionally, integrin-related signalling was explored by anti-integrin-linked kinase (ILK; clone 3, dilution 1 : 1000), anti-focal adhesion kinase (FAK; clone 77, dilution 1 : 1000) and anti-phospho-specific FAK (pY397; clone 18, dilution 1 : 1000) antibodies (all: BD Biosciences). HRP-conjugated goat-anti-mouse IgG (Upstate Biotechnology, Lake Placid, NY, USA; dilution 1 : 5.000) served as the secondary antibody. The membranes were briefly incubated with ECL detection reagent (ECL, Amersham/GE Healthcare, München, Germany) to visualise the proteins and then analysed by the Fusion FX7 system (Peqlab, Erlangen, Germany). b-actin (1 : 1.000; Sigma, Taufenkirchen, Germany) served as the internal control.
Real-time (RT)-qPCR
RT-qPCR was also done in triplicate. cDNA synthesis was performed using 3 mg of total RNA per sample according to the manufacturer's protocol by AffinityScript QPCR cDNA Synthesis Kit (Stratagene, Amsterdam, The Netherlands). Quantitative geneexpression analysis by RT-PCR was performed by the Mx3005p (Stratagene) using SYBR-Green SuperArray (SABioscience Corporation, Valencia, CA, USA) and SuperArray primer sets: GAPDH (NM_002046.3, Hs.592355), integrin a1 (ITGA1, NM_181501, Hs.644352), integrin a2 (ITGA2, NM_002203, Hs.482077), integrin a3 (ITGA3, NM_002204, Hs.265829), integrin a4 (ITGA4, NM_000885, Hs.694732), integrin a5 (ITGA5, NM_002205, Hs.505654), integrin a6 (ITGA6, NM_000210, Hs.133397), integrin b1 (ITGB1, NM_002211, Hs.643813), integrin b3 (ITGB3, NM_000212, Hs.218040) and integrin b4 (ITGB4, NM_000213, Hs.632226; all: SABioscience Corporation). Calculation of the relative expression of each gene was done by the DDCt method in the analysis programme of SABioscience Corporation. The housekeeping gene GAPDH was used for normalisation.
Cell signalling
Cell signalling was explored by using the following monoclonal antibodies: Akt (IgG1, clone 55, dilution 1 : 500), phospho Akt (pAkt; IgG1, clone 104A282, dilution 1 : 500), EGFr (IgG1, clone 13/EGFR, dilution 1 : 500), phospho EGFr (pEGFr; IgG1, clone 74, dilution 1 : 1000), ERK1 (IgG1, clone MK12, dilution 1 : 5000), ERK2 (IgG2b, clone 33, dilution 1 : 5000), phospho ERK1/2 (pERK; IgG1, clone 20A, dilution 1 : 1000; all: BD Biosciences), p70S6k (IgG, clone 49D7, dilution 1 : 1000) and phospho p70S6k (pp70S6k; IgG, clone 108D2, dilution 1 : 1000; all: New England Biolabs, Frankfurt, Germany).
Blocking studies
PC3
par and PC3 res cells were preincubated for 60 min with function-blocking anti-integrin b1 (clone 6S6), anti-integrin a2 (clone P1E6) or anti-integrin a5 (clone P1D6; all: Millipore, Schwalbach, Germany) monoclonal antibodies (20 mg ml À 1 ). Controls remained untreated. Cells were then subjected to the chemotaxis and migration assay as indicated above. Adhesion to immobilised collagen was evaluated additionally. An anti-Akt function-blocking antibody was used to analyse the influence of Akt on PC3 par and PC3 res cell chemotaxis (Akt inhibitor VIII, 20 mg ml À 1 ; Chemdea, Ridgewood, NJ, USA).
Statistics
All experiments were performed three to six times. Statistical significance was investigated by the Wilcoxon Mann-Whitney U-test. Differences were considered statistically significant at a P-value o0.05.
RESULTS
Adhesion characteristics
Dynamic evaluation of tumour cell-endothelial cell interaction revealed that more PC3 par cells adhered to HUVEC over time than did PC3 res cells ( Figure 1A ). Addition of 5 nM RAD001 significantly reduced the adhesion capacity of PC3 par but not of PC3 res cells. A similar phenomenon was seen in the extracellular matrix binding assay. More PC3 par cells bound to immobilised collagen, laminin or fibronectin than PC3 res cells ( Figure 1B ), and application of 5 nM RAD001 resulted in a diminished attachment rate of PC3 par but not of PC3 res cells.
Tumour motility, migration and invasion
Chemotactic movement was significantly elevated in PC3 res , compared with PC3 par cells (Figure 2A ). Furthermore, application of 5 nM RAD001 blocked chemotaxis of PC3 par but strongly increased the motile activity of PC3 res cells. PC3 res cells also tended to cross collagen ( Figure 2B ) or HUVEC ( Figure 2C ) at a higher rate than PC3 par cells did. The addition of 5 nM RAD001 decreased migration and invasion of PC3 par cells. In contrast, migration and invasion of PC3 res cells were upregulated in the presence of 5 nM RAD001. Figure 2D shows Integrins are modified in PC3 res cells
Surface levels of integrin a and b adhesion receptors were analysed next. The integrin subtypes a2, a3, a6, b1 and b4 were strongly expressed, a1 and a5 were moderately expressed and b3 was not expressed on PC3 par cells (Figure 3 ). The a4 integrin subtype was not detected by flow cytometry, either on PC3 par or PC3 res cells (data not shown). PC3 res cells were characterised by distinct differences in the integrin-expression pattern, compared with the controls. The a2 and b1 subtypes were dramatically elevated. Integrins a1 and a6 were lowered, whereas a5 was nearly lost on the PC3 res cell membrane. The b3 subtype appeared on PC3 res cells. Only slight differences were seen with respect to the a3 and b4 integrins. In a further experimental setting, PC3 res and PC3 par cells were treated short-term with 5 nM RAD001. Integrin a2 and b1 expression (most altered under chronic RAD001 treatment) was then evaluated. Exposing PC3 par cells to RAD001 led to an upregulation of a2 (þ 69.7 ± 14.8%) and b1 (þ 39.7 ± 7.6%), compared with untreated PC3 par cells. Short-term treatment of PC3 res cells with RAD001 also evoked an upregulation of a2 ( þ 14.2±4.9%) and b1 ( þ 17.3±4.0%), although to a lesser extent than in PC3 par cells. Western blotting demonstrated slight elevation of a2, a3 and b4 integrins in PC3 res cells, compared with the control cell line. Notably, the b1 protein content was found to be drastically upregulated in cells resistant to RAD001 ( Figure 4A ). In contrast, the a4 integrin protein, which was detectable in the PC3 par cytoplasm, as well as the a5 integrin, was suppressed in PC3 res cells. Protein bands specific for the a1 and b3 integrin were not seen in the cell cultures. FAK, pFAK and ILK analysis showed similar protein amounts in drug-resistant compared with drugsensitive tumour cells.
Additionally, integrin-coding genes were evaluated. The most distinct differences became evident on a5 integrin mRNA, which was expressed in PC3 res at a very low level, compared with the PC3 par cells ( Figure 4B ). There was also a significant reduction of a1, a4 and a6 integrins, accompanied by an enhancement of b4 integrin mRNA in the resistant compared with non-resistant cells.
Cell signalling is altered in PC3 res cells 
Blocking studies
To investigate the functionality of b1 and a2 integrins, which were strongly elevated in PC3 res , compared with PC3 par cells, blocking studies were carried out. Figure 6 
DISCUSSION
Despite encouraging preclinical and clinical results of mTOR inhibitors, resistance has emerged as a problem. Because metastasis is a critical step in tumour dissemination and progression, the consequences of RAD001 resistance in prostate cancer adhesion and invasion was investigated in the present study. The PC3 res cells were defined by an IC 50 value for RAD001, which was 70-fold higher than that for PC3 par cells (Tsaur et al, 2011) . Evidence is presented here that drug non-responsiveness is coupled to downregulation of tumour adhesion to endothelial cells and extracellular matrix proteins, accompanied by increased chemotactic activity. Tumour-cell amoeboid motility is necessary for metastasis (Yilmaz and Christofori, 2010; van Zijl et al, 2011) . Hence, the differences seen between PC3 res and PC3 par cells indicate that long-term exposure to RAD001 alters intracellular mechanisms, which are closely involved in controlling metastatic spread. The differences in the motile behaviour of PC3 res and PC3 par cells became particularly evident in the chemotaxis assay, which only evaluates cell movement. Differences were not clearly seen in the migration and invasion assay, probably because these res cells were treated with fresh medium (without RAD001) for 3 days and then added to immobilised collagen, laminin or fibronectin for 60 min. drug treatment, therefore, may drive the tumour cell to acquire a more invasive phenotype, and continuing RAD001 application may further accelerate the metastatic dissemination.
Evaluation of the mechanism responsible for the elevated motile behaviour of PC3 res cells points to a modified integrin-expression pattern. Particularly, the a2 and b1 subtypes were upregulated, whereas the a5 subtype was absent in the drug-resistant cells. The role of a2 in prostate cancer metastasis is not yet clear. Neal et al (2011) have reported that a2 expression inversely correlates with prostate cancer cell migration into collagen, whereas the opposite was seen by Van Slambrouck et al (2009) . Based on our own blocking studies, increased a2 seems more likely connected with elevated motile behaviour, because functional blocking of the integrin a2 subunit distinctly inhibited both chemotactic movement and migration through a collagen matrix. The blocking effect was significantly stronger in the resistant sublines than in the parental cells. This is important. Obviously, metastatic spreading of RAD001-resistant prostate cancer is accelerated by two strategies: (1) by upregulating the a2 expression level (quantitative regulation) and (2) by strengthening the relevance of a2 in controlling invasion (qualitative regulation). In fact, cell migration has been demonstrated to depend on the number of a2 integrin receptors expressed on the cell surface (Li et al, 2011) , as well as on qualitative parameters, such as activation of intracellular signalling cascades and/or receptor cross-talk (Ning et al, 2005; Sawhney et al, 2006) . We assume that the conversion of prostate cancer cells from a drug-sensitive to a drug-insensitive state is accompanied by an elevated a2 level, a2-cytoskeleton interaction and cytoskeletonrelated signalling, finally enforcing actin turnover and remodelling.
The same mode of action may be attributed to b1 as to a2 integrin receptors, because b1 blockade leads to a distinct downregulation of chemotaxis and migration (PC3 res 4PC3 par ). However, the role of the b1 receptor seems to be complex. Blocking b1 also reduced tumour cell adhesion properties. Because b1 was strongly increased in the PC3 res variant, an enhanced attachment rate of these cells, compared with the controls, could be expected, but was not the case. PC3
res -HUVEC and PC3 res -matrix interaction were even lowered. Consequently, integrin b1 may not serve as a pure mechanistic binding element. Live cell imaging of fibroblast spreading has demonstrated that b1 undergoes an affinity switch, which allows disassembly of adhesion structures and dynamic crawling (Millon-Frémillon et al, 2008) . In line with this, alteration of b1-actin cross-linking has been reported to weaken adhesion and increase migratory activity of cancer cells (Mouneimne and Brugge, 2007) . Chronic treatment with RAD001 possibly induces a functional switch in PC3 cells. In fact, a greater dependency of tumour migration on b1 was seen in the resistant compared with the non-resistant cell line. With this in mind, b1 (as well as a2) integrin elevation in PC3 par induced by short-term RAD001 application may strengthen adhesive forces and thereby prevent motile spreading, whereas the same effect may cause enhanced chemotactic activity of PC3 res cells. In fact, treating PC3 par cells with RAD001 led to a significant reduction of tumour cell chemotaxis, migration and invasion, whereas short-term treatment of PC3 res cells with RAD001 evoked the opposite effect. The interpretation of the integrin data obtained after short-term RAD001 treatment is speculative. However, the same integrin has recently been shown to control cell spreading and retraction by switching the direction of integrin outside-in signalling (Flevaris et al, 2007) . Deshmukh et al (2011) have provided a complex paradigm where integrin function depends on the secondary structure pattern and overall folding of the integrin cytoplasmic tail, shifting the integrin influence to different signalling proteins and the intracellular pathways. Therefore, it seems plausible that resistance development of PC3 cells may be accompanied by two different processes: (A) quantitative alterations of the integrin-expression level and (B) structural changes of the integrin molecules, leading to a switch of the intracellular pathway direction following short-term RAD001 treatment. PC3 par PC3 res Figure 5 Western blot analysis of cell signalling proteins, listed in methods. PC3 par or PC3 res cells remained untreated (control). They were kept for 2 h in serum-free cell culture medium and subsequently stimulated for 30 min with EGF (100 ng ml À 1 ; þ EGF) or they were stimulated with EGF and additionally treated with 5 nM RAD001 ( þ EGF þ RAD001). Cell lysates were then subjected to SDS-PAGE and blotted on the membrane incubated with the respective monoclonal antibodies. b-actin served as the internal control. The figure shows one representative from three separate experiments. Apart from being involved in metastasis, b1 integrins are required for Akt phosphorylation and contribute to cell survival and growth (Riaz et al, 2012) . Downregulation of b1 in prostate cancer cells inhibited Akt activation and retarded tumour proliferation (Niewiarowska et al, 2009; Goel et al, 2010) . Meanwhile, b1 is considered to be a key component in regulating the conversion from a dormant state to active proliferation and metastasis (Barkan and Chambers, 2011) . Our data point to a strong activation of Akt (along with EGFr and pERK) in PC3 res cells. We cannot definitively declare that the massive accumulation of b1 in PC3 res cells activates growth-related signals, because we did not analyse b1-Akt cross communication. However, Akt activation points towards a speed up of the cell-cycle machinery. It is of particular interest that b1 has been shown to contribute to chemoresistance in head and neck (Eke et al, 2012) , pancreatic (Danilov et al, 2011) , breast (Huang et al, 2011) , lung (Ju et al, 2010) and ovarian cancer (Chen et al, 2010a) , and targeting b1 integrins has provided benefit in overcoming drug non-responsiveness (Mori et al, 2008; Park et al, 2008; Huang et al, 2011) . Whatever the precise mechanism of b1 in PC3 res is, it represents a significant prognostic and therapeutic marker molecule. From a clinical viewpoint, patients should be carefully controlled when a b1 increase becomes overt. Ongoing studies should explore whether b1 increases during chronic RAD001 treatment and whether this increase correlates with resistance development in cancer patients.
An interesting phenomenon is seen with respect to the a5 integrin. Blocking a5 led to decreased adhesion and increased chemotaxis and migration of PC3 par cells. It has recently been postulated that a5 may be crucial for cell detachment and subsequent metastasis of prostate cancer (Neal et al, 2011) , which is in line with our results. However, this relationship does not seem transferable to the PC3 res cells, whose adhesion properties were only slightly, and motile behaviour not at all, modified following a5 blockade. Another mode of action must be assumed here. Experiments with breast , melanoma (Landreville et al, 2011) or colon cancer cells (De Wever et al, 2011) have shown that a5 subunit functions as a tumour-growth suppressor. Indeed, a link between the a5 integrin and cell-cycle controlling proteins exists, because overexpression of a5 triggers downregulation of CDK2, thereby inhibiting cellular entry into the S phase . Vice versa, loss of a5 as seen in the PC3 res cells may trigger enhanced CDK2 expression, resulting in elevated mitotic activity. This is speculative. However, a recent publication points to the accumulation of CDK1 and CDK2 in RAD001-resistant prostate cancer cells (Tsaur et al, 2011) , which supports our hypothesis that the reduction of a5 evoked by longterm RAD001 exposure may cause an increase in tumour growth.
With respect to intracellular signalling, the most striking differences were seen in the activation level of Akt, which was strongly enhanced in PC3 res compared with PC3 par cells. Much data point to the relevance of this protein in resistance development. Upregulation of phosphorylated Akt has been shown to correlate to docetaxel resistance and progression to castrationresistant prostate cancer after androgen ablation (Kosaka et al, 2011) . Evidence has also been provided that the Akt pathway has Chemotaxis -anti-1 Chemotaxis -anti-2 Chemotaxis -anti-5
Migration -anti-1 Migration -anti-2 Migration -anti-5 Figure 6 Influence of integrin a2, a5 or b1 blockade on tumour cell adhesion, chemotaxis or migration. PC3 par or PC3 res cells were preincubated for 60 min with function-blocking anti-integrin b1, anti-integrin a2 or anti-integrin a5 monoclonal antibodies. Controls remained untreated. Cells were then subjected to the adhesion, chemotaxis and migration assay as indicated in Materials and Methods. Values are shown as percentage difference to the 100% control. *indicates significant difference between the PC3 control subline and the PC3 subline treated with the function-blocking antibody. # indicates significant difference between PC3 par and PC3 res cells whose integrin subtype was blocked.
an important role in TRAIL resistance in cancer cells (Xu et al, 2010) . It is not clear how long-term inhibition of mTOR triggers Akt activation. mTOR consists of two complexes, mTORC1, which is located downstream of Akt and is sensitive to mTOR inhibitors, and mTORC2, which is upstream of Akt and is resistant to mTOR inhibitors (Ma and Blenis, 2009 ). Long-term application of RAD001 may, therefore, induce feedback activation of Akt via mTORC2 signalling. Concerning metastatic progression, activation of the Akt pathway has been shown to correlate with the chemotactic motility of prostate cancer cells in vitro (Jeong et al, 2012) and prostate tumour progression to metastasis in the transgenic adenocarcinoma mouse prostate mouse model (Sakamoto et al, 2010) . Indeed, Akt blockade strongly diminished chemotaxis of PC3 par cells, which corroborates both reports. Surprisingly, chemotactic activity of PC3 res cells was not diminished following Akt blockade, perhaps indicating uncoupling of the integrin-Akt axis during resistance development. Similarly, Chen et al (2010b) recently observed an uncoupling of the Akt-connected pathways in drugresistant breast cancer cells. This finding could be clinically relevant because therapeutic suppression of Akt may no longer prevent metastatic progression once tumour cells have acquired resistance. Whether the action of Akt in PC3 res cells is exclusively focused on increasing the tumour mass (e.g., by speeding up tumour cell proliferation and blocking apoptosis) is not yet clear.
This study demonstrates that RAD001 resistance drives prostate cancer cells to become highly motile. The process is accompanied by significant alterations of the integrin-expression profile, particularly a2, a5 and a1, and by reactivating Akt. Further studies should be directed towards answering whether a5 integrin undergoes a functional switch from adhesion/migration to proliferation under chronic RAD001 treatment and whether Akt is connected to integrins during resistance development.
